Cancer incidence in patients with polyglutamine diseases: A population-based study in Sweden

The Lancet Oncology

Volumn 13, Issue 6, 2012, Pages 642-648

  Ji, Jianguang ^a   Sundquist, Kristina ^a   Sundquist, Jan ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; DEGENERATIVE DISEASE; FEMALE; HEREDITARY ATAXIA; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MAJOR CLINICAL STUDY; MALE; POLYGLUTAMINE DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SWEDEN;

ADULT; AGE DISTRIBUTION; AGED; DATABASES, FACTUAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; NEURODEGENERATIVE DISEASES; PEPTIDES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SWEDEN;

EID: 84861563268     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70132-8     Document Type: Article

References (36)

1. Paulson HL, Bonini NM, Roth KA Polyglutamine disease and neuronal cell death. Proc Natl Acad Sci USA 2000, 97:12957-12958.
2. Gatchel JR, Zoghbi HY Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005, 6:743-755.
3. Ross CA Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
4. Shao J, Diamond MI Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 2007, 16:R115-R123.
5. Walker FO Huntington's disease. Lancet 2007, 369:218-228.
6. Klockgether T Update on degenerative ataxias. Curr Opin Neurol 2011, 24:339-345.
7. Durr A Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010, 9:885-894.
8. Nucifora FC, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
9. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000, 97:6763-6768.
10. Bae BI, Xu H, Igarashi S, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47:29-41.
11. Sorensen SA, Fenger K, Olsen JH Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract?. Cancer 1999, 86:1342-1346.
12. Tabarés-Seisdedos R, Dumont N, Baudot A, et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 2011, 12:604-608.
13. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 2010, 6:e1001257.
14. O'Sullivan Smith C, Michelson SJ, Bennett RL, Bird TD Spinocerebellar ataxia: making an informed choice about genetic testing (accessed March 22, 2012). http://depts.washington.edu/neurogen/downloads/ataxia.pdf.
15. Cancer incidence in Sweden 2007 National Board of Health and Welfare, (accessed March 22, 2012). http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/8715/2008-125-16_200812516_rev2.pdf.
16. Rothman KJ, Greenland S Modern epidemiology 1998, Lippincott-Raven, Philadelphia, PA. 2nd edn.
17. Statistical methods in cancer research: volume II-the design and analysis of cohort studies 1987, International Agency for Research on Cancer, Lyon. N.E. Breslow, N.E. Day (Eds.).
18. Statistical methods in cancer research: volume IV-descriptive epidemiology 1994, International Agency for Research on Cancer, Lyon. J. Esteève, E. Benhamou, L. Raymond (Eds.).
19. Ehret JC, Day PS, Wiegand R, Wojcieszek J, Chambers RA Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families. Drug Alcohol Depend 2007, 86:283-286.
20. Martindale D, Hackam A, Wieczorek A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998, 18:150-154.
21. Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001, 98:12784-12789.
22. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993, 4:393-397.
23. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993, 4:398-403.
24. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993, 4:387-392.
25. MacLean HE, Warne GL, Zajac JD Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. J Neurol Sci 1996, 135:149-157.
26. MacLean HE, Choi WT, Rekaris G, Warne GL, Zajac JD Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy). J Clin Endocrinol Metab 1995, 80:508-516.
27. Biancalana V, Serville F, Pommier J, Julien J, Hanauer A, Mandel JL Moderate instability of the trinucleotide repeat in spino bulbar muscular atrophy. Hum Mol Genet 1992, 1:255-258.
28. Friedman JH, Trieschmann ME, Myers RH, Fernandez HH Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol 2005, 62:995-997.
29. Georgiou N, Bradshaw JL, Chiu E, Tudor A, O'Gorman L, Phillips JG Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord 1999, 14:320-325.
30. Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol 2012, published online Jan 25. 10.1007/s00415-012-6415-8.
31. Muller PA, Vousden KH, Norman JC p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011, 192:209-218.
32. Levine AJ, Oren M The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
33. Schuller HM Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?. Nat Rev Cancer 2009, 9:195-205.
34. Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet 2002, 11:1967-1976.
35. Lazebnik Y What are the hallmarks of cancer?. Nat Rev Cancer 2010, 10:232-233.
36. Ludvigsson JF, Andersson E, Ekbon A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011, 11:450.